Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluorescence Intraoperative Surgical Margin Analysis in Head and Neck Cancer
2025-522027-95-00Phase 3Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of cetuximab in Oral Mucosal Carcinoma (2 arms), sponsored by University Medical Center Groningen. Planned start Jan 2026; status: authorised.
02
Drugs
cetuximab
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on 2025-522027-95-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522027-95-00.